Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(25.0%)
N/A
1(25.0%)
Phase 1
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 3(1)
N/A(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05080829Not ApplicableUnknown

Myeloid Mutations Register in R/R CML

Role: lead

NCT04288765Phase 3Withdrawn

Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Role: lead

NCT04296214Withdrawn

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Role: lead

NCT04334044Phase 1Completed

Treatment of SARS Caused by COVID-19 With Ruxolitinib

Role: lead

NCT03755947Phase 2Completed

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Role: lead

All 5 trials loaded